Isoflavone (DB12007): A Comprehensive Pharmacological, Clinical, and Regulatory Review

Executive Summary and Compound Identification

Executive Summary

Isoflavone (DB12007) is the parent compound of a class of biologically active phytoestrogens, predominantly found in soybeans and other leguminous plants. Chemically classified as a small molecule, it serves as the structural backbone for key dietary isoflavones such as genistein, daidzein, and glycitein. These compounds are also categorized as Selective Estrogen Receptor Modulators (SERMs) due to their tissue-specific estrogenic and antiestrogenic activities, which are mediated by a preferential binding affinity for estrogen receptor beta ($ER\beta$) over estrogen receptor alpha ($ER\alpha$). The bioavailability and ultimate physiological effect of dietary isoflavones are critically dependent on biotransformation by the gut microbiome, which converts inactive glycosides into absorbable, active aglycones. This metabolic step, particularly the conversion of daidzein to the more potent metabolite equol, is highly variable among individuals and represents a major determinant of clinical response.

Extensive clinical research has investigated the therapeutic potential of isoflavones, with the most robust evidence supporting a modest but statistically significant reduction in the frequency and severity of menopausal vasomotor symptoms. Evidence also indicates that consistent intake can attenuate postmenopausal bone mineral density loss. The role of isoflavones in cardiovascular health is nuanced; while isolated supplements have minimal impact on lipid profiles, dietary intake is associated with improved vascular function and a moderately lower risk of coronary heart disease. The safety profile of isoflavones is generally favorable, particularly when consumed as part of whole soy foods. However, high-dose supplements warrant caution, especially in individuals with hormone-sensitive cancers or thyroid disorders, and have a significant potential for pharmacokinetic drug interactions. Globally, isoflavones occupy a complex regulatory space, classified not as pharmaceuticals but as dietary supplements or listed medicines, leading to significant variability in product standardization and a disconnect between their potent biological mechanism and the level of regulatory oversight.

Table 1: Compound Identification and Properties

Property	Value	Source(s)
Primary Name	Isoflavone	1
Systematic (IUPAC) Name	3-phenylchromen-4-one	3
DrugBank ID	DB12007	1
CAS Number	574-12-9	1
Type/Modality	Small Molecule	1
Synonyms	3-Phenylchromone, 3-phenyl-4H-1-benzopyran-4-one, NSC 135405	2
Molecular Formula	$C_{15}H_{10}O_2$	2
Molecular Weight	222.24 g/mol	2
InChI	$InChI=1S/C15H10O2/c16-15-12-8-4-5-9-14(12)17-10-13(15)11-6-2-1-3-7-11/h1-10H$	3
InChIKey	GOMNOOKGLZYEJT-UHFFFAOYSA-N	3
Canonical SMILES	$C1=CC=C(C=C1)C2=COC3=CC=CC=C3C2=O$	3
Other Database IDs	PubChem CID: 72304, ChEBI: 18220, UNII: OVO2KUW8H8	2

Chemical Profile, Natural Sources, and Biosynthesis

2.1. Chemical Structure and Classification

Isoflavone is a naturally occurring compound belonging to the flavonoid family of polyphenols.[9] Its fundamental chemical structure is a 3-phenylchromen-4-one backbone, which consists of two benzene rings (A and B) linked by a heterocyclic pyrone ring (C).[2] This structure makes it an isomer of flavone, in which the phenyl B-ring is attached at the C2 position of the pyrone ring; in isoflavone, this attachment is at the C3 position.[2]

The parent isoflavone compound is the scaffold for a variety of substituted derivatives that are of primary biological and dietary importance.[6] The principal isoflavones found in soy are genistein, daidzein, and glycitein, which differ in the hydroxylation and methoxylation patterns on their phenolic rings.[13] In soybeans, these three compounds account for approximately 50%, 40%, and 10% of the total isoflavone content, respectively.[1]

In their natural state within plants, isoflavones predominantly exist as glycosides (e.g., genistin, daidzin, glycitin), where one or more hydroxyl groups are conjugated to a sugar molecule, typically glucose.[1] This glycosylation renders the molecules more water-soluble and stable for storage within the plant tissue.[10] However, these glycoside forms are biologically inactive in humans as they cannot be readily absorbed by the intestine.[18] Biological activity is conferred only after the sugar moiety is cleaved through hydrolysis, releasing the aglycone form (e.g., genistein, daidzein).[1] This chemical distinction between the inactive, naturally occurring glycoside and the active, absorbable aglycone is the first and most critical determinant of isoflavone bioavailability and subsequent pharmacological effect. The entire potential of dietary isoflavones hinges upon this initial biotransformation, creating a crucial bottleneck in the gastrointestinal tract that introduces significant inter-individual variability in response.

2.2. Natural Occurrence and Dietary Sources

Isoflavones are synthesized by a limited number of plant families, with the Fabaceae (legume) family being the most significant source.[10] Among all dietary sources, soybeans (Glycine max) and food products derived from them are exceptionally rich in isoflavones, making them the primary source in the human diet.[1] Other legumes containing notable amounts of isoflavones include chickpeas, peanuts, green peas, alfalfa, kudzu root, and red clover.[1]

The concentration and profile of isoflavones in food products vary widely depending on the type of food, processing methods, and even between different brands of the same product.[17] For example, traditional soy foods like tempeh and miso, which undergo fermentation, contain a higher proportion of readily absorbable aglycones compared to unfermented products.[19] Conversely, highly processed soy ingredients, such as alcohol-washed soy protein concentrate, may have a significantly reduced isoflavone content compared to aqueous-washed concentrates or whole soybeans.[17] This variability is a critical factor when assessing dietary intake and interpreting the results of epidemiological studies. The disparity in average daily isoflavone intake between Asian populations (25–50 mg/day) and Western populations (often <5 mg/day) is largely attributable to differences in the consumption of these soy-based foods.[17]

Table 2: Isoflavone Content of Common Foods and Soy-Based Products

Disclaimer: Isoflavone content can vary considerably between brands and processing methods. These values should be viewed as a general guide. [17]

Food	Serving Size	Total Isoflavones (mg)	Source(s)
Soy protein concentrate, aqueous washed	3.5 oz (100 g)	94.6 - 102	17
Miso	½ cup	57 - 59	17
Soybeans, mature, boiled	½ cup	47 - 56	17
Tempeh	3 oz	37 - 51.5	17
Soybeans, dry roasted	1 oz	37 - 41.6	17
Soy milk	1 cup (8 oz)	6.2 - 30	17
Tofu, soft	3 oz	19.2 - 20	17
Edamame (green soybeans), boiled	½ cup	16.1	17
Soy protein concentrate, alcohol washed	3.5 oz (100 g)	11.5 - 12	17

2.3. Biosynthesis and Biological Role in Plants

In higher plants, isoflavones are synthesized via a specific branch of the general phenylpropanoid pathway, which is responsible for producing a wide array of flavonoid compounds.[10] The pathway begins with the amino acid phenylalanine, which is converted through a series of enzymatic steps into flavonoid intermediates. In legumes, specific enzymes such as isoflavone synthase then divert these intermediates to produce the characteristic 3-phenylchromen-4-one isoflavone backbone.[10]

From an ecophysiological perspective, isoflavones are not merely inert secondary metabolites; they play crucial, active roles in the plant's survival and interaction with its environment. Their primary functions include acting as phytoalexins, which are antimicrobial compounds produced by the plant in response to attack by pathogenic fungi and other microbes.[10] Additionally, isoflavones serve as key signaling molecules in the symbiotic relationship between legumes and nitrogen-fixing soil bacteria of the genus Rhizobium. The plant roots excrete isoflavones to attract these bacteria and induce the formation of root nodules, where the bacteria convert atmospheric nitrogen into a form usable by the plant.[10]

Comprehensive Pharmacological Profile

3.1. Mechanism of Action (Pharmacodynamics)

3.1.1. Phytoestrogen and Selective Estrogen Receptor Modulator (SERM) Activity

The pharmacological activity of isoflavones is defined by their dual classification as both phytoestrogens and Selective Estrogen Receptor Modulators (SERMs). They are termed phytoestrogens because they are plant-derived compounds with a phenolic structure that bears a striking resemblance to the endogenous mammalian estrogen, 17β-estradiol.[1] This structural similarity allows them to bind to and activate estrogen receptors, thereby exerting weak estrogen-like effects.[2]

More importantly, isoflavones are classified as SERMs, a designation that captures the complexity of their actions far better than "phytoestrogen" alone.[1] A SERM is a compound that exhibits tissue-specific effects, acting as an estrogen agonist in some tissues while functioning as an estrogen antagonist in others.[19] This paradoxical behavior is central to understanding the clinical profile of isoflavones. For example, they may exert beneficial estrogenic effects in bone tissue while simultaneously exhibiting antiestrogenic effects in breast and uterine tissue, depending on the local hormonal environment and the relative expression of estrogen receptor subtypes.[1]

3.1.2. Interaction with Estrogen Receptors (ERα and ERβ)

The molecular basis for the SERM activity of isoflavones lies in their differential interaction with the two main isoforms of the estrogen receptor: estrogen receptor alpha ($ER\alpha$) and estrogen receptor beta ($ER\beta$).[1] While isoflavones can bind to both receptor types, they exhibit a distinct and significant preferential binding affinity for $ER\beta$, which is reported to be approximately 20 times higher than their affinity for $ER\alpha$.[1] Studies focusing on genistein have noted this preference to be as high as 40-fold.[26]

This preferential binding is profoundly important because the two receptor isoforms often mediate different, and sometimes opposing, physiological responses. Broadly, activation of $ER\alpha$ is associated with proliferative effects, particularly in the breast and endometrium, whereas activation of $ER\beta$ is often linked to anti-proliferative actions and cellular differentiation.[19] By preferentially activating $ER\beta$, isoflavones can trigger a distinct downstream signaling cascade compared to endogenous estradiol, which binds to both receptors with high and roughly equal affinity.[27] This differential signaling allows isoflavones to act as estrogen agonists in tissues where $ER\beta$-mediated effects are dominant (e.g., bone, cardiovascular system) and as functional antagonists in tissues where they compete with the more potent estradiol for $ER\alpha$ binding (e.g., breast tissue in premenopausal women), thereby reducing the overall proliferative signal.

3.1.3. Comparative Potency vs. Endogenous Estrogens

In terms of intrinsic potency, isoflavones are weak estrogens. Their binding affinity for estrogen receptors and their ability to initiate gene transcription are significantly lower than that of endogenous 17β-estradiol, estimated to be anywhere from 100 to 1,000 times weaker.[19]

However, this low intrinsic potency is offset by their high bioavailability from dietary sources. Following consumption of soy-rich foods or supplements, the circulating plasma concentrations of isoflavones can reach levels that are several orders of magnitude higher—up to 10,000 times—than the levels of endogenous estradiol, particularly in postmenopausal women whose natural estrogen production has declined.[30] This sheer abundance allows the weakly potent isoflavones to occupy a significant number of estrogen receptors and elicit a meaningful biological response, effectively compensating for their low per-molecule activity.[29]

3.1.4. Estrogen Receptor-Independent Mechanisms

Beyond their interaction with estrogen receptors, isoflavones exert a range of biological effects through ER-independent pathways.[17] These non-hormonal actions contribute significantly to their overall pharmacological profile.

• Enzyme Inhibition: Isoflavones, particularly genistein, are known inhibitors of protein tyrosine kinases. These enzymes are crucial components of intracellular signaling pathways that regulate cell growth, proliferation, and differentiation. By inhibiting these kinases, isoflavones can disrupt the signaling cascades that drive abnormal cell proliferation, an action that first prompted investigation into their anti-cancer potential.[17]
• PPAR Modulation: Isoflavones can modulate the activity of Peroxisome Proliferator-Activated Receptors, specifically $PPAR\alpha$ and $PPAR\gamma$. These nuclear receptors are master regulators of genes involved in lipid and glucose homeostasis. By influencing PPAR activity, isoflavones can affect lipid metabolism and glucose regulation, which may underlie some of their observed cardioprotective effects.[1]
• Antioxidant Activity: Isoflavones possess direct antioxidant properties. They can scavenge free radicals and inhibit the production of reactive oxygen species, thereby protecting cells from oxidative damage.[1]

3.2. Pharmacokinetics (Absorption, Distribution, Metabolism, Excretion - ADME)

3.2.1. Absorption

The pharmacokinetic journey of dietary isoflavones begins with absorption, a process entirely dependent on their chemical form. The inactive glycosides abundant in food cannot be absorbed intact.[18] The mandatory first step is hydrolysis to release the absorbable aglycones. This conversion is initiated by β-glucosidase enzymes in the oral cavity and small intestine (e.g., lactase phlorizin hydrolase) and is completed by bacterial enzymes in the large intestine.[1] Once liberated, the more lipophilic aglycones are absorbed from the intestinal lumen into the enterocytes primarily via passive diffusion.[1] The form of isoflavone ingested—aglycone-rich fermented foods versus glycoside-rich unfermented foods—can influence the rate and location of absorption, with aglycones leading to a faster rise in plasma concentrations.[32]

3.2.2. Metabolism

Metabolism of isoflavones is extensive and is dominated by two key processes: first-pass conjugation and biotransformation by the gut microbiota.

• First-Pass Metabolism: Immediately upon absorption into intestinal enterocytes and subsequent passage to the liver, isoflavone aglycones undergo rapid Phase II metabolism. They are extensively conjugated to form glucuronide and sulfate derivatives. As a result, isoflavones enter the systemic circulation predominantly as biologically inactive conjugates.[1]
• Role of Gut Microbiota: The gut microbiome plays a dual, pivotal role that extends beyond initial de-glycosylation. It is also responsible for the subsequent metabolism of the aglycones themselves into a variety of secondary metabolites.[20] This metabolic activity is highly variable between individuals, acting as a "second genome" that profoundly influences the ultimate biological effect of soy consumption.
• Equol Production: The most clinically significant of these microbial transformations is the conversion of daidzein into equol, a metabolite with a chiral center that exists as S-(-)-equol in humans.[20] This conversion is carried out by specific consortia of gut bacteria, and the capacity to perform this conversion is not universal. Only about 30–50% of individuals in Western populations are classified as "equol producers".[17] This is a critical factor, as equol exhibits greater biological activity, a higher binding affinity for estrogen receptors (particularly $ER\beta$), and a longer half-life than its precursor, daidzein.[20] The inability of a majority of the population to produce this more potent metabolite likely explains much of the inconsistency observed in clinical trials of soy isoflavones. This suggests that studies failing to stratify participants by equol-producer status may be underpowered, with the potential benefits seen in producers being diluted by the lack of response in non-producers.

3.2.3. Distribution and Excretion

After entering the systemic circulation (mostly as conjugates), isoflavones and their metabolites are distributed throughout the body. They are known to undergo enterohepatic circulation, where they are excreted into the bile, deconjugated by gut bacteria, reabsorbed, and returned to the liver, prolonging their presence in the body.[28] The primary route of final elimination is through the kidneys, with metabolites excreted in the urine as glucuronide and sulfate conjugates.[28] The mean elimination half-life ($t_{1/2}$) for total (free plus conjugated) genistein and daidzein is approximately 8 to 9 hours, indicating that consistent daily intake is required to maintain steady-state plasma concentrations.[39] Some studies have noted that pharmacokinetic parameters such as half-life can be influenced by factors like sex and the duration of soy intake.[40]

Evidence-Based Review of Therapeutic Applications

4.1. Management of Menopausal Symptoms

Vasomotor Symptoms (Hot Flashes)

The use of isoflavones as an alternative to hormone replacement therapy (HRT) for the management of menopausal vasomotor symptoms is one of the most extensively studied applications. A substantial body of evidence from multiple systematic reviews and meta-analyses indicates that isoflavone supplementation provides a statistically significant, though modest, reduction in the frequency and severity of hot flashes when compared to placebo.[31] One comprehensive meta-analysis reported an average reduction in hot flash frequency of 20.6% and a reduction in severity of 26.2%.[42] While effective, the magnitude of this effect is less than that of conventional HRT, with one analysis suggesting isoflavones are about 40% less efficient.[17] The clinical benefit may be more pronounced in women who experience a high number of hot flashes at baseline.[41] Furthermore, the specific composition of the supplement appears to be important; those providing a higher dose of genistein (e.g., >18.8 mg per day) have been shown to be more than twice as potent in reducing hot flash frequency.[42]

Other Menopausal Symptoms

The evidence for isoflavones' effects on other menopausal symptoms is more varied. For urogenital symptoms such as vaginal dryness, the findings are inconsistent. While some reviews suggest a modest benefit, others have found no conclusive effect.[30] A meta-analysis focused specifically on vaginal atrophy did not find a statistically significant improvement in the vaginal maturation index, a key objective measure.[45] More recent research has begun to parse out effects on other symptoms. A meta-analysis published in late 2024 found that isoflavone supplementation was associated with significant improvements in headache, psychosocial symptoms (such as anxiety and low mood), and palpitations. However, the same analysis found no significant effect on insomnia or fatigue.[46]

4.2. Osteoporosis and Postmenopausal Bone Health

The decline in estrogen during menopause accelerates bone turnover, leading to a net loss of bone mass and an increased risk of osteoporosis. Given their estrogen-like properties, isoflavones have been widely investigated for their potential to preserve bone health. The proposed mechanism involves mimicking estrogen's bone-sparing effects by inhibiting bone resorption by osteoclasts and stimulating bone formation by osteoblasts, primarily through interaction with $ER\beta$ in bone cells.[49]

A consistent finding across numerous meta-analyses of randomized controlled trials (RCTs) is that daily supplementation with isoflavones (typically at doses of 80 mg/day or more for at least six to twelve months) can moderately but significantly attenuate the loss of bone mineral density (BMD) in menopausal women.[44] The protective effect is most consistently observed at the lumbar spine and femoral neck.[50] This effect is generally characterized as a slowing of bone loss rather than a substantial rebuilding of bone mass. The evidence regarding bone turnover markers has been more mixed historically [56], but a large meta-analysis from December 2024, including 73 RCTs, provided stronger evidence, showing that isoflavone interventions significantly reduced markers of bone resorption (e.g., β-CrossLaps) and favorably modulated bone minerals and regulatory hormones like insulin-like growth factor 1 (IGF-1).[57]

4.3. Cardiovascular Health

The relationship between isoflavones and cardiovascular health is multifaceted, with effects on lipid profiles, blood pressure, and overall disease risk.

• Lipid Profile: Early enthusiasm for soy's ability to lower cholesterol, which led to a 1999 FDA health claim for soy protein, has been significantly tempered by subsequent research.[58] A major 2006 scientific advisory from the American Heart Association (AHA) concluded from a review of 22 randomized trials that while large amounts of isolated soy protein (averaging 50 g/day) can lower LDL cholesterol, the effect is very small—only about 3% on average.[59] Critically, the advisory found that isolated isoflavone supplements had no significant effect on LDL cholesterol or other lipid markers.[59] The modest benefit of soy foods on cholesterol is now largely attributed to the displacement of foods high in saturated fat and cholesterol, rather than a direct pharmacological effect of the isoflavones themselves.
• Blood Pressure and Arterial Function: More promising evidence has emerged regarding isoflavones' effects on vascular health. A 2024 meta-analysis concluded that supplementation significantly reduces both systolic and diastolic blood pressure.[61] Another meta-analysis found that isoflavones improve measures of arterial stiffness, such as pulse wave velocity, which is an independent predictor of future cardiovascular events.[62]
• Cardiovascular Disease Risk: Epidemiological data from large prospective cohort studies provide further support for a cardiovascular benefit. Meta-analyses have found that higher dietary intake of isoflavones and tofu is associated with a moderately lower risk of developing coronary heart disease (CHD).[63] An interesting and somewhat counterintuitive finding is that this protective association appears to be stronger in Western populations than in Asian populations.[63] This "Western paradox" may be a statistical artifact; in Western populations with very low baseline intake, the contrast between low and high consumers is stark, making an effect easier to detect. In Asian populations, even the "low-intake" group may consume enough isoflavones to receive a benefit, creating a ceiling effect that masks a dose-response relationship.

4.4. Oncology: Cancer Risk and Survivorship

The role of isoflavones in hormone-sensitive cancers, particularly breast cancer, is the most controversial area of research, fueled by conflicting results from animal and human studies.

• Breast Cancer Risk: Initial concerns arose from early animal studies where high doses of isolated isoflavones stimulated the growth of estrogen-dependent tumors in rodents.[66] However, it is now understood that rodents metabolize isoflavones differently than humans, resulting in much higher circulating levels of the active compounds, making these models poorly representative of human exposure.[68] In stark contrast, a large body of human observational evidence, especially from Asian countries where soy consumption is lifelong, consistently shows that higher dietary intake of soy foods is associated with a reduced risk of developing breast cancer.[66] This protective effect may be most pronounced when soy is consumed during childhood and adolescence.[17]
• Breast Cancer Survivorship: A significant concern for patients and clinicians has been whether soy consumption after a breast cancer diagnosis could interfere with endocrine therapies like tamoxifen or promote recurrence. A growing consensus, supported by major health organizations like the American Cancer Society, now indicates that moderate consumption of whole soy foods (e.g., 1-2 servings per day) is safe for breast cancer survivors.[66] Furthermore, several large observational studies have suggested that soy consumption in this population is associated with a reduced risk of cancer recurrence and mortality.[17] It is critical to distinguish this from high-dose isoflavone supplements, for which safety in this population has not been established and which are generally not recommended.[66]
• Prostate and Other Cancers: The evidence for other cancers is less developed. Some studies suggest that isoflavone consumption may lower markers of prostate cancer progression, such as prostate-specific antigen (PSA), but the data from clinical trials are currently insufficient to support a role in prevention or treatment.[1]

4.5. Investigational and Other Uses

Research into the therapeutic applications of isoflavones continues to expand into new areas. A notable example is a Phase 2 clinical trial that is actively recruiting participants to investigate the effects of isoflavone on asthma in children.[72] This trial suggests a novel line of inquiry into the potential anti-inflammatory properties of isoflavones beyond their hormonal effects. Additionally, preliminary research in skin health has shown promise; one study in postmenopausal women demonstrated that six months of daily supplementation with 100 mg of isoflavones significantly improved several markers of skin aging, including increased epidermal thickness, collagen and elastic fiber content, and vascularity.[73]

Safety, Tolerability, and Risk Profile

5.1. Adverse Effects and General Safety Profile

The safety profile of isoflavones is highly dependent on the source and dose. When consumed at dietary levels from whole soy foods, isoflavones have a long history of safe use and are associated with numerous health benefits.[74] In clinical trials, isoflavone supplements have also been shown to be generally well-tolerated, with a safety profile often comparable to placebo in short- to medium-term studies (up to two years).[30]

When adverse effects do occur, they are most commonly mild and gastrointestinal in nature. These include symptoms such as nausea, bloating, constipation, and diarrhea.[30] As soy is a major allergen, true allergic reactions are also possible and can be severe, manifesting as skin rash, hives, angioedema, and respiratory distress.[80]

5.2. Contraindications, Warnings, and Precautions

While generally safe for the broader population, the use of isoflavone supplements warrants caution in specific groups due to their hormonal activity. A nuanced risk assessment must consider the source (food vs. supplement), the dose, and the specific health status of the individual.

• Hormone-Sensitive Cancers: This remains the area of greatest concern. While moderate intake of whole soy foods is now considered safe for breast cancer survivors, the safety of high-dose, isolated isoflavone supplements in this population is not established.[44] Regulatory bodies like Health Canada mandate explicit warnings on supplements providing ≥30 mg/day for individuals with a history or predisposition to breast cancer.[82] Caution is also advised for those with a history of other hormonal or gynecological diseases, such as ovarian cancer or endometriosis.[80]
• Thyroid Disease: Isoflavones can act as goitrogens by inhibiting the enzyme thyroid peroxidase, which is essential for thyroid hormone synthesis. This effect is generally considered clinically insignificant in individuals with adequate iodine intake but may become relevant in those with pre-existing hypothyroidism or iodine deficiency.[44] Furthermore, soy products can interfere with the intestinal absorption of levothyroxine medication, necessitating dose separation.[83]
• Pregnancy and Lactation: Due to a lack of sufficient safety data and theoretical concerns about endocrine disruption during critical developmental windows, high-dose isoflavone supplements are not recommended during pregnancy or breastfeeding.[44]
• Infant Formula: Infants fed soy-based formula are exposed to circulating isoflavone levels that are orders of magnitude higher than those in breast-fed infants or even adults consuming a high-soy diet.[85] While decades of use have not produced convincing evidence of widespread harm, concerns persist regarding potential long-term effects on endocrine, reproductive, and immune development.[17]

5.3. Significant Drug and Supplement Interactions

Isoflavones have a significant potential to interact with a wide range of medications. These interactions are primarily pharmacokinetic, arising from the ability of isoflavones to modulate the activity of crucial drug-metabolizing enzymes (particularly the cytochrome P450 system) and drug transporters (such as P-glycoprotein).[83] By inhibiting or inducing these pathways, isoflavones can alter the absorption, distribution, metabolism, and excretion (ADME) of co-administered drugs, thereby affecting their efficacy and toxicity. Clinicians should be aware of these potential interactions, especially when patients are taking high-dose supplements.

Table 3: Summary of Clinically Significant Isoflavone Drug Interactions

Interacting Drug/Class	Potential Interaction and Clinical Implication	Mechanism	Source(s)
Anticoagulants / Antiplatelets (e.g., Warfarin, NSAIDs)	Decreased efficacy of warfarin, potentially increasing clotting risk. Synergistic effects with other agents may increase bleeding risk.	Reduced warfarin effect; pharmacodynamic synergism.	83
Hormonal Therapies (e.g., Estrogens, Tamoxifen)	Potential for antagonistic interactions. May decrease the effects of oral estrogens or alter the efficacy of SERMs like tamoxifen.	Competitive binding at estrogen receptors.	83
Thyroid Hormones (e.g., Levothyroxine)	Decreased intestinal absorption of levothyroxine, leading to reduced efficacy and potential hypothyroidism.	Impaired absorption.	83
CYP450 Substrates (Various drugs)	Altered plasma concentrations of drugs metabolized by CYP enzymes (e.g., CYP2C9, CYP3A4), affecting their efficacy and/or toxicity. Examples include celecoxib, paclitaxel, midazolam, omeprazole.	Inhibition or induction of CYP450 enzymes.	83
Antibiotics	May reduce the population of gut bacteria responsible for converting isoflavone glycosides to active aglycones, potentially decreasing the efficacy of isoflavones.	Disruption of gut microbiome.	83

Regulatory and Commercial Landscape

6.1. Global Regulatory Status

Isoflavones occupy a complex and inconsistent regulatory landscape globally. They exist in a gray zone between food and medicine, classified not as conventional pharmaceutical drugs but as dietary supplements, food ingredients, or low-risk medicines. This classification means they are not subject to the rigorous pre-market approval process for safety and efficacy required for pharmaceuticals, which contributes to issues with product standardization and the substantiation of health claims. The regulatory approach differs significantly between major international bodies.

This fundamental disconnect between the potent, drug-like SERM mechanism of isoflavones and the lower level of regulatory scrutiny they receive is a central challenge. It creates a paradox where efforts to purify and standardize a product to ensure consistent biological activity—making it more like a reliable drug—can risk violating the regulatory definition of a "natural" or "herbal" substance. This was starkly illustrated by Australia's Therapeutic Goods Administration (TGA), which cancelled the listing of an isoflavone product because its manufacturing involved purification and concentration steps deemed too "drug-like" and outside the permitted processes for a "herbal substance".[91] This tension highlights the difficulties in regulating potent bioactive compounds derived from natural sources.

Table 4: Comparative Overview of Regulatory Status (USA, Europe, Australia)

Region / Agency	Classification	Key Regulations and Opinions	Key Requirements and Warnings
USA (FDA)	Dietary Supplement / Food Ingredient	- 1999 Health claim for soy protein and CHD risk (currently under review for revocation).58- Regulated under the Dietary Supplement Health and Education Act (DSHEA).- GRAS notice for soy isoflavone extract (GRN No. 1) was filed but later withdrawn by the notifier.93	- Not subject to pre-market approval for safety/efficacy.81- Manufacturers are responsible for ensuring safety.- Claims are limited to structure/function, not disease treatment/prevention.
European Union (EFSA)	Food Supplement	- 2015 Scientific Opinion concluded no evidence of harm from supplements (up to 150 mg/day) for post-menopausal women on breast, uterus, or thyroid.94- No official health-based guidance value (e.g., Tolerable Upper Intake Level) has been established.	- Safety opinion is limited to post-menopausal women and specific doses/durations.- Data for other populations (e.g., peri-menopausal, those with cancer history) were deemed insufficient.95- Health claims related to various benefits have been reviewed, often with insufficient evidence for substantiation.97
Australia (TGA)	Ingredient for Listed Medicines	- Included in the Therapeutic Goods (Permissible Ingredients) Determination.98- Products are "listed" on the Australian Register of Therapeutic Goods (ARTG) as low-risk medicines.	- Sponsors must hold evidence to support indications but do not submit it for pre-market evaluation.99- Manufacturing process is restricted; purification steps can render a product ineligible for listing as a "herbal substance".91

6.2. Industrial Production and Market Overview

The commercial production of isoflavone supplements and functional food ingredients is a significant global industry. The global isoflavones market was valued at over USD 16.5 billion in 2022 and is projected to continue growing, driven by strong consumer demand for plant-based nutrition, nutraceuticals, and natural alternatives for managing health conditions like menopausal symptoms.[101]

• Extraction and Purification: Industrial-scale production typically begins with soybean flour, soy germ, or soy molasses as the raw material.[103] Conventional extraction methods involve the use of organic solvents like ethanol, methanol, or acetone to isolate the isoflavone-rich fraction.[104] This crude extract then undergoes purification steps, which may include column chromatography or the use of macroporous adsorption resins to concentrate the isoflavones and separate them from other compounds.[106] In recent years, there has been a shift toward more advanced and environmentally friendly "green" extraction technologies, such as ultrasound-assisted extraction (UAE), microwave-assisted extraction (MAE), and supercritical fluid extraction (SFE), which can improve yield, reduce solvent use, and shorten processing times.[108]
• Commercial Products and Standardization: The final products are marketed as dietary supplements, often in tablet or capsule form, or incorporated into functional foods and beverages.[101] A persistent issue in the supplement market is the lack of standardization and consistency. Studies analyzing commercial products have found significant variability in the isoflavone profile (i.e., the ratio of genistein, daidzein, etc.) and the total quantity of active compounds. The actual content often differs from the label claim, particularly when the content is expressed in terms of the more biologically relevant aglycone equivalents versus the total glycosides.[112] This lack of standardization complicates clinical research and makes it difficult for consumers and clinicians to rely on a consistent dose.

Expert Synthesis and Concluding Remarks

Holistic Synthesis

Isoflavone and its dietary derivatives represent a class of compounds with a uniquely complex and context-dependent biological profile. They are not simple estrogens, but rather sophisticated Selective Estrogen Receptor Modulators (SERMs) whose physiological effects are intricately dictated by a confluence of factors. The ultimate clinical outcome of isoflavone consumption depends on the source (whole food versus isolated supplement), the dose (dietary versus pharmacological), the host's endogenous hormonal environment (pre- vs. post-menopause), and, critically, the metabolic capacity of the individual's gut microbiome. The preferential binding to $ER\beta$ provides a molecular basis for their tissue-specific actions, explaining their potential to confer benefits in some systems (e.g., bone) while acting neutrally or antagonistically in others (e.g., breast). The significant variability in clinical trial outcomes is largely a reflection of this complexity, particularly the failure of many studies to account for inter-individual differences in metabolism, such as equol production. While evidence supports modest benefits for menopausal symptoms and bone health, the broader perception of isoflavones must evolve from a simplistic view of "plant estrogen" to a nuanced understanding of a multi-target, microbiome-dependent bioactive compound.

Expert Recommendations for Clinical Practice

Based on the current body of evidence, the following recommendations can be made for clinical practice:

1. Emphasize Dietary Sources: For the general population, particularly postmenopausal women, the inclusion of 1-2 daily servings of whole soy foods (e.g., tofu, tempeh, edamame, soy milk) is a prudent recommendation. This approach is supported by a strong safety record in epidemiological studies and offers potential benefits for cardiovascular and bone health, likely due to the combined effects of isoflavones, high-quality protein, fiber, and other nutrients within the whole food matrix.
2. Employ Supplements with Caution and Specificity: High-dose isoflavone supplements should not be considered a direct or equivalent substitute for conventional medical therapies, such as hormone replacement therapy for severe menopausal symptoms or bisphosphonates for osteoporosis. Their use should be targeted for specific, evidence-supported indications, such as the modest relief of mild-to-moderate hot flashes. Patients should be counseled that the effect is less potent than HRT and may take longer to manifest.
3. Advise Against Use in High-Risk Groups: Given the unresolved questions regarding long-term safety and hormonal effects, the use of high-dose isoflavone supplements should be discouraged in individuals with a personal history of hormone-sensitive malignancies (e.g., breast cancer), undiagnosed gynecological conditions, or poorly controlled thyroid disease. Any use in these populations must be undertaken only after a thorough risk-benefit discussion with their specialist physician. Patients on multiple medications, especially anticoagulants, should be warned of the potential for significant drug interactions.

Identification of Knowledge Gaps and Future Research Directions

Despite decades of research, significant knowledge gaps remain. Future investigation should prioritize the following areas to provide definitive clarity:

• Long-Term Safety of Supplements: There is a critical lack of long-term (>3 years), large-scale, randomized controlled trials evaluating the safety of high-dose isoflavone supplements, particularly with respect to the risk of hormone-sensitive cancers.
• Stratification by Equol Status: It is imperative that future clinical trials on the efficacy of isoflavones stratify participants by their equol-producer status. This single factor may account for much of the heterogeneity in past results. Concurrently, research into the efficacy and safety of co-administering specific probiotics to convert non-producers into producers is a highly promising therapeutic avenue.
• Product Standardization: The clinical and research communities would benefit immensely from the development of standardized, well-characterized isoflavone preparations. A lack of consistency in the composition (isoflavone profile) and form (aglycone vs. glycoside content) of commercial supplements remains a major barrier to comparing study results and providing reliable clinical dosing.
• Expansion to New Populations and Indications: Research should expand beyond the primary focus on postmenopausal women to better understand the effects of isoflavones in men, children, and different ethnic groups. Novel investigations into non-hormonal effects, such as the ongoing trial in pediatric asthma [72], are essential for exploring the full therapeutic potential of these compounds.

Works cited

1. Isoflavone: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 24, 2025, https://go.drugbank.com/drugs/DB12007
2. Isoflavone | 574-12-9 - ChemicalBook, accessed October 24, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3466698.htm
3. Isoflavone | C15H10O2 | CID 72304 - PubChem - NIH, accessed October 24, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Isoflavone
4. CAS 574-12-9 Isoflavone - Alfa Chemistry, accessed October 24, 2025, https://www.alfa-chemistry.com/product/isoflavone-cas-574-12-9-292729.html
5. ISOFLAVONE - precisionFDA, accessed October 24, 2025, https://precision.fda.gov/ginas/app/ui/substances/294c3ba8-0b39-40cc-abf9-48e2e6b39d04
6. Isoflavone (3-Phenylchromone, NSC 135405, CAS Number: 574-12-9) | Cayman Chemical, accessed October 24, 2025, https://www.caymanchem.com/product/33964/isoflavone
7. Isoflavone | The Merck Index Online - The Royal Society of Chemistry, accessed October 24, 2025, https://merckindex.rsc.org/monographs/m6489
8. Isoflavone | CAS NO.:574-12-9 - GlpBio, accessed October 24, 2025, https://www.glpbio.com/isoflavone.html
9. CAS 574-12-9: Isoflavone - CymitQuimica, accessed October 24, 2025, https://cymitquimica.com/cas/574-12-9/
10. Isoflavone - Wikipedia, accessed October 24, 2025, https://en.wikipedia.org/wiki/Isoflavone
11. pubchem.ncbi.nlm.nih.gov, accessed October 24, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Isoflavone#:~:text=Isoflavone%20is%20a%20simplest%20member,replaced%20by%20a%20phenyl%20group.
12. Metabolic Engineering of Isoflavones: An Updated Overview - Frontiers, accessed October 24, 2025, https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2021.670103/full
13. Isoflavones | [Analytical Chemistry]Products - FUJIFILM Wako Chemicals, accessed October 24, 2025, https://labchem-wako.fujifilm.com/us/category/01799.html
14. Chemical structure of soy isoflavones, such as daidzein, genistein, and... - ResearchGate, accessed October 24, 2025, https://www.researchgate.net/figure/Chemical-structure-of-soy-isoflavones-such-as-daidzein-genistein-and-glycitein_fig2_221732785
15. sniglobal.org, accessed October 24, 2025, https://sniglobal.org/soy-isoflavones/#:~:text=The%20three%20isoflavones%20in%20soybeans,10%25%2C%20respectively%2C%20of%20the
16. Isoflavones in Soy-Based Infant Formulas | Journal of Agricultural and Food Chemistry, accessed October 24, 2025, https://pubs.acs.org/doi/10.1021/jf970590t
17. Soy Isoflavones | Linus Pauling Institute | Oregon State University, accessed October 24, 2025, https://lpi.oregonstate.edu/mic/dietary-factors/phytochemicals/soy-isoflavones
18. Isoflavones: Estrogenic activity, biological effect and bioavailability - ResearchGate, accessed October 24, 2025, https://www.researchgate.net/publication/233538635_Isoflavones_Estrogenic_activity_biological_effect_and_bioavailability
19. Soy Isoflavones | Learn More | SNI Institute, accessed October 24, 2025, https://sniglobal.org/soy-isoflavones/
20. Pharmacokinetics of Dietary Isoflavones, accessed October 24, 2025, https://www.iomcworld.com/open-access/pharmacokinetics-of-dietary-isoflavones-2157-7536.S12-004.pdf
21. Soybeans and soy foods | Better Health Channel, accessed October 24, 2025, https://www.betterhealth.vic.gov.au/health/healthyliving/soybeans
22. Soy Foods And Their Protein and Isoflavone Content - Evidence Analysis Library, accessed October 24, 2025, https://www.andeal.org/template.cfm?template=food_tables&key=300
23. Isoflavones: estrogenic activity, biological effect and bioavailability - PubMed, accessed October 24, 2025, https://pubmed.ncbi.nlm.nih.gov/23161396/
24. the-role-of-isoflavones-in-hormonal-balance-for-women.pdf - Oxidants and Antioxidants in Medical Science, accessed October 24, 2025, https://www.ejmoams.com/ejmoams-articles/the-role-of-isoflavones-in-hormonal-balance-for-women.pdf
25. Do Isoflavones Exert Estrogen-Like Effects in Women? - SNI Global, accessed October 24, 2025, https://sniglobal.org/do-isoflavones-exert-estrogen-like-effects-in-women/
26. Evaluation of Synthetic Isoflavones on Cell Proliferation, Estrogen Receptor Binding Affinity, and Apoptosis in Human Breast Cancer Cells - PMC - NIH, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3638921/
27. Plant Phytoestrogens and Estrogen Differences - Soy Connection, accessed October 24, 2025, https://www.soyconnection.com/old-pages/soy-information-health-professionals/differentiating-between-plant-phytoestrogens-and-estrogen-fact-sheet
28. Current Perspectives on the Beneficial Effects of Soybean Isoflavones and Their Metabolites for Humans - MDPI, accessed October 24, 2025, https://www.mdpi.com/2076-3921/10/7/1064
29. Potential Health Benefits of Dietary Phytoestrogens: A Review of the Clinical, Epidemiological, and Mechanistic Evidence1 - Oxford Academic, accessed October 24, 2025, https://academic.oup.com/jcem/article/83/7/2223/2865105
30. Isoflavone Supplements for Menopausal Women: A Systematic Review - PMC - NIH, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6893524/
31. Isoflavone Supplements for Menopausal Women: A Systematic Review - MDPI, accessed October 24, 2025, https://www.mdpi.com/2072-6643/11/11/2649
32. Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer - NIH, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4633369/
33. The metabolism and analysis of isoflavones and other dietary polyphenols in foods and biological systems - PMC - NIH, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4122511/
34. Pharmacokinetics of Dietary Isoflavones - Semantic Scholar, accessed October 24, 2025, https://www.semanticscholar.org/paper/Pharmacokinetics-of-Dietary-Isoflavones-Ch-rasekharan/96b884c92e2de6c7637bb6b6904eba773efb6a8d
35. Scientific Publications by FDA Staff, accessed October 24, 2025, http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=51142
36. Interaction of phytoestrogens with estrogen receptors alpha and beta - PubMed, accessed October 24, 2025, https://pubmed.ncbi.nlm.nih.gov/11305594/
37. Classification and biological activity of phytoestrogens: A review - ResearchGate, accessed October 24, 2025, https://www.researchgate.net/publication/322223467_Classification_and_biological_activity_of_phytoestrogens_A_review
38. The production and metabolism of different isoflavones in humans.... - ResearchGate, accessed October 24, 2025, https://www.researchgate.net/figure/The-production-and-metabolism-of-different-isoflavones-in-humans-Isoflavones-are_fig1_353204320
39. Clinical characteristics and pharmacokinetics of purified soy isoflavones: Single-dose administration to healthy men - ResearchGate, accessed October 24, 2025, https://www.researchgate.net/publication/11601720_Clinical_characteristics_and_pharmacokinetics_of_purified_soy_isoflavones_Single-dose_administration_to_healthy_men
40. Sex and long-term soy diets affect the metabolism and excretion of soy isoflavones in humans - UTMB Research Experts, accessed October 24, 2025, https://researchexperts.utmb.edu/en/publications/sex-and-long-term-soy-diets-affect-the-metabolism-and-excretion-o
41. Isoflavone therapy for menopausal flushes: A systematic review and meta-analysis | Request PDF - ResearchGate, accessed October 24, 2025, https://www.researchgate.net/publication/7106063_Isoflavone_therapy_for_menopausal_flushes_A_systematic_review_and_meta-analysis
42. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: Systematic review and meta-analysis of randomized controlled trials - ResearchGate, accessed October 24, 2025, https://www.researchgate.net/publication/221877513_Extracted_or_synthesized_soybean_isoflavones_reduce_menopausal_hot_flash_frequency_and_severity_Systematic_review_and_meta-analysis_of_randomized_controlled_trials
43. Full article: Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review - Taylor & Francis Online, accessed October 24, 2025, https://www.tandfonline.com/doi/full/10.3109/13697137.2014.966241
44. Benefits and Risks of Taking Isoflavones - Verywell Health, accessed October 24, 2025, https://www.verywellhealth.com/isoflavones-benefits-side-effects-dosage-and-interactions-4687017
45. Effects of Phytoestrogens in Alleviating the Menopausal Symptoms: A Systematic Review and Meta-Analysis - Brieflands, accessed October 24, 2025, https://brieflands.com/articles/ijpr-124890
46. Effects of soy isoflavones on menopausal symptoms in perimenopausal women: a systematic review and meta-analysis - ResearchGate, accessed October 24, 2025, https://www.researchgate.net/publication/393950908_Effects_of_soy_isoflavones_on_menopausal_symptoms_in_perimenopausal_women_a_systematic_review_and_meta-analysis
47. Soy isoflavones can ease some menopause symptoms - Study Summary - Examine.com, accessed October 24, 2025, https://examine.com/research-feed/study/dpPAQd/
48. Effects of soy isoflavones on menopausal symptoms in perimenopausal women: a systematic review and meta-analysis - NIH, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12296567/
49. Soy Isoflavones and Osteoporotic Bone Loss: A Review with an Emphasis on Modulation of Bone Remodeling - PMC - NIH, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4717511/
50. The Role of Soy Isoflavones in the Prevention of Bone Loss in Postmenopausal Women: A Systematic Review with Meta-Analysis of Randomized Controlled Trials - NIH, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9409780/
51. Effects of soybean isoflavone aglycone on osteoporosis in ovariectomized rats - Frontiers, accessed October 24, 2025, https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1122045/full
52. Skeletal benefits of soy isoflavones: A review of the clinical trial and epidemiologic data, accessed October 24, 2025, https://experts.llu.edu/en/publications/skeletal-benefits-of-soy-isoflavones-a-review-of-the-clinical-tri-2
53. (PDF) The Role of Soy Isoflavones in the Prevention of Bone Loss in Postmenopausal Women: A Systematic Review with Meta-Analysis of Randomized Controlled Trials - ResearchGate, accessed October 24, 2025, https://www.researchgate.net/publication/362630310_The_Role_of_Soy_Isoflavones_in_the_Prevention_of_Bone_Loss_in_Postmenopausal_Women_A_Systematic_Review_with_Meta-Analysis_of_Randomized_Controlled_Trials
54. Isoflavones for bone mineral density in postmenopausal women - Study Summary, accessed October 24, 2025, https://examine.com/research-feed/study/dVWeJ1/
55. Soy isoflavones for bone mineral density after menopause - Study Summary - Examine.com, accessed October 24, 2025, https://examine.com/research-feed/study/W9KpEd/
56. Effects of Soy Isoflavones on Biochemical Markers of Bone Metabolism in Postmenopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - MDPI, accessed October 24, 2025, https://www.mdpi.com/1660-4601/18/10/5346
57. Effects of isoflavone interventions on bone turnover markers and factors regulating bone metabolism in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials - PubMed, accessed October 24, 2025, https://pubmed.ncbi.nlm.nih.gov/39708251
58. Federal Register/Vol. 64, No. 206/Tuesday, October 26, 1999/Rules and Regulations - GovInfo, accessed October 24, 2025, https://www.govinfo.gov/content/pkg/FR-1999-10-26/pdf/99-27693.pdf
59. Soy Protein, Isoflavones, and Cardiovascular... : Circulation - Ovid, accessed October 24, 2025, https://www.ovid.com/journals/circ/fulltext/10.1161/circulationaha.106.171052~soy-protein-isoflavones-and-cardiovascular-health-an
60. Soy Protein, Isoflavones, and Cardiovascular Health | Circulation - AHA Journals, accessed October 24, 2025, https://www.ahajournals.org/doi/10.1161/circulationaha.106.171052?doi=10.1161/CIRCULATIONAHA.106.171052
61. Effect of soy isoflavone supplementation on blood pressure: a meta-analysis of randomized controlled trials - NIH, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10918941/
62. The Effect of Soy Isoflavones on Arterial Stiffness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - PMC, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7728657/
63. Soy isoflavone intake and risk of cardiovascular disease in adults: A systematic review and dose-response meta-analysis of prospective cohort studies - PubMed, accessed October 24, 2025, https://pubmed.ncbi.nlm.nih.gov/36705465/
64. Isoflavone Intake and the Risk of Coronary Heart Disease in US Men and Women | Circulation, accessed October 24, 2025, https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.041306
65. Is soy isoflavone intake associated with the risk of cardiovascular disease? - Study Summary, accessed October 24, 2025, https://examine.com/research-feed/study/dnxPD0/
66. Soy and Cancer Risk: Our Expert's Advice | American Cancer Society, accessed October 24, 2025, https://www.cancer.org/cancer/latest-news/soy-and-cancer-risk-our-experts-advice.html
67. Safety of isoflavones in dietary supplements targeted by Illinois initiative, accessed October 24, 2025, https://news.illinois.edu/safety-of-isoflavones-in-dietary-supplements-targeted-by-illinois-initiative/
68. Soy and Cancer, Studies Indicate No Increased Risk - AICR, accessed October 24, 2025, https://www.aicr.org/cancer-prevention/food-facts/soy/
69. Soy Isoflavones and Breast Cancer Risk: A Meta-analysis - In Vivo, accessed October 24, 2025, https://iv.iiarjournals.org/content/36/2/556
70. Is isoflavone intake linked to lower breast cancer risk? - Study Summary - Examine.com, accessed October 24, 2025, https://examine.com/research-feed/study/dpbEv0/
71. Isoflavones, accessed October 24, 2025, https://s10901.pcdn.co/wp-content/uploads/2021/06/Concerns-about-the-Safety-of-Soyfoods-without-Scientific-Foundation.pdf
72. Asthma in Children Recruiting Phase 2 Trials for Isoflavone (DB12007) | DrugBank Online, accessed October 24, 2025, https://go.drugbank.com/indications/DBCOND0054551/clinical_trials/DB12007?phase=2&status=recruiting
73. Effects of Isoflavones on the Skin of Postmenopausal Women: A Pilot Study - Elsevier, accessed October 24, 2025, https://www.elsevier.es/en-revista-clinics-22-articulo-effects-isoflavones-on-skin-postmenopausal-S1807593222026084
74. (PDF) Soy Isoflavones: A Safety Review - ResearchGate, accessed October 24, 2025, https://www.researchgate.net/publication/10855804_Soy_Isoflavones_A_Safety_Review
75. Soy isoflavones: a safety review - PubMed, accessed October 24, 2025, https://pubmed.ncbi.nlm.nih.gov/12638461/
76. SOY FOODS AND SUPPLEMENTS - My Menoplan, accessed October 24, 2025, https://mymenoplan.org/soy-foods-and-supplements/
77. Soy isoflavones in postmenopausal women: a review of current evidence - e-Century Publishing Corporation, accessed October 24, 2025, https://e-century.us/files/ajceog/8/1/ajceog0144070.pdf
78. Scientific Evidence Supporting the Beneficial Effects of Isoflavones on Human Health - PMC, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7766685/
79. pmc.ncbi.nlm.nih.gov, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6893524/#:~:text=3.8.-,Side%20Effects,due%20to%20previous%20animal%20studies.
80. Soy Isoflavones oral dosage forms - Cleveland Clinic, accessed October 24, 2025, https://my.clevelandclinic.org/health/drugs/20099-soy-isoflavones-oral-dosage-forms
81. Soy Isoflavones Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed October 24, 2025, https://www.webmd.com/drugs/2/drug-18270/soy-isoflavones-oral/details
82. Technical Report - To summarize the scientific rationale for the Natural Health Products Directorate's new guidance on the regulation of soy isoflavone products - Canada.ca, accessed October 24, 2025, https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription/legislation-guidelines/guidance-documents/technical-report-summarize-scientific-rationale-regulation-isoflavone.html
83. SOY: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews - WebMD, accessed October 24, 2025, https://www.webmd.com/vitamins/ai/ingredientmono-975/soy
84. Soy: Usefulness and Safety | NCCIH, accessed October 24, 2025, https://www.nccih.nih.gov/health/soy
85. Isoflavone content of infant formulas and the metabolic fate of these phytoestrogens in early life - PubMed, accessed October 24, 2025, https://pubmed.ncbi.nlm.nih.gov/9848516/
86. Focus on Phytoestrogens - U.S. Pharmacist, accessed October 24, 2025, https://www.uspharmacist.com/article/focus-on-phytoestrogens
87. Isoflavones in Soybean as a Daily Nutrient: The Mechanisms of Action and How They Alter the Pharmacokinetics of Drugs - NIH, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8744443/
88. Dietary Isoflavones as Modulators of Drug Metabolizing Enzymes and Transporters: Effect on Prescription Medicines - PubMed, accessed October 24, 2025, https://pubmed.ncbi.nlm.nih.gov/26561312/
89. Indication-specific dosing for (phytoestrogens), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information. - Medscape Reference, accessed October 24, 2025, https://reference.medscape.com/drug/isoflavones-daidzein-phytoestrogens-344513
90. pmc.ncbi.nlm.nih.gov, accessed October 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8744443/#:~:text=Drug%20interactions%20occur%20when%20other%20substances%20affect%20the%20activity%20of%20a%20drug.&text=These%20interactions%20may%20occur%20with,22%20levodopa%2C23%20and%20ciprofloxacin.
91. FOI-079-1112 document 17 - Therapeutic Goods Administration (TGA), accessed October 24, 2025, https://www.tga.gov.au/sites/default/files/foi-079-1112-17.pdf
92. FOI-079-1112 document 18 - Therapeutic Goods Administration (TGA), accessed October 24, 2025, https://www.tga.gov.au/sites/default/files/foi-079-1112-18.pdf
93. GRAS Notices - cfsanappsexternal.fda.gov, accessed October 24, 2025, https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=1
94. Isoflavone Supplements Are Safe According to the European Food Safety Authority, accessed October 24, 2025, https://sniglobal.org/isoflavone-supplements-are-safe-according-to-the-european-food-safety-authority/
95. Isoflavones in food supplements for post-menopausal women: no evidence of harm | EFSA, accessed October 24, 2025, https://www.efsa.europa.eu/en/press/news/151021
96. Safety of isoflavones from food supplements in menopausal women - EFSA, accessed October 24, 2025, https://www.efsa.europa.eu/en/efsajournal/pub/4246
97. Soy isoflavone related health claims - EFSA - European Union, accessed October 24, 2025, https://www.efsa.europa.eu/en/efsajournal/pub/2264
98. Update to listed medicine ingredients in March 2025, accessed October 24, 2025, https://www.tga.gov.au/news/notices/update-listed-medicine-ingredients-march-2025
99. Listed medicines | Therapeutic Goods Administration (TGA), accessed October 24, 2025, https://www.tga.gov.au/products/medicines/non-prescription-medicines/listed-medicines
100. Update to listed medicine ingredients in March 2024, accessed October 24, 2025, https://www.tga.gov.au/news/notices/update-listed-medicine-ingredients-march-2024
101. Isoflavones Market Share 2023-2032 | Global Statistics Report, accessed October 24, 2025, https://www.gminsights.com/industry-analysis/isoflavones-market
102. Isoflavone Supplements Market Size, Report and Major Companies 2024-2031, accessed October 24, 2025, https://www.datamintelligence.com/research-report/isoflavone-supplements-market
103. Integrated extraction and purification of soy isoflavones by using aqueous micellar systems - CONICET, accessed October 24, 2025, https://ri.conicet.gov.ar/bitstream/handle/11336/52830/CONICET_Digital_Nro.86903411-7168-4e0f-b97f-b44ff0f6e3f1_A.pdf?sequence=2&isAllowed=n
104. Extraction and Purification of Isoflavones from Soybeans and Characterization of Their Estrogenic Activities | Journal of Agricultural and Food Chemistry - ACS Publications, accessed October 24, 2025, https://pubs.acs.org/doi/abs/10.1021/jf0708903
105. Extraction, characterization and microencapsulation of isoflavones from soybean molasses, accessed October 24, 2025, https://www.scielo.br/j/cr/a/tjhHz5QfNbQT53Bc4qdFDGb/?lang=en
106. CN1069903C - Method for extracting isoflavone from soybean - Google Patents, accessed October 24, 2025, https://patents.google.com/patent/CN1069903C/en
107. Adsorption and Desorption Characteristics and Purification of Isoflavones from Crude Soybean Extract Using Macroporous Resins - Polish Journal of Food and Nutrition Sciences, accessed October 24, 2025, https://journal.pan.olsztyn.pl/Adsorption-and-Desorption-Characteristics-and-Purification-of-Isoflavones-from-Crude,149816,0,2.html
108. Extraction of Flavonoids From Natural Sources Using Modern Techniques - Frontiers, accessed October 24, 2025, https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2020.507887/full
109. Methods of Analysis of Phytoestrogenic Compounds: An Up-to-Date of the Present State, accessed October 24, 2025, https://www.mdpi.com/2297-8739/11/7/205
110. Extraction Methods for the Isolation of Isoflavonoids from Plant Material - Semantic Scholar, accessed October 24, 2025, https://www.semanticscholar.org/paper/Extraction-Methods-for-the-Isolation-of-from-Plant-Blicharski-Oniszczuk/df8dd72162fc4b9b90165e3a3236f99d204f15c7
111. SoyLife® Isoflavone – IFF Health Sciences, accessed October 24, 2025, https://www.iff.com/health-sciences/our-products/soylife/
112. Determination of the isoflavone composition and estrogenic activity of commercial dietary supplements based on soy or red clover - Food & Function (RSC Publishing) DOI:10.1039/C5FO00308C, accessed October 24, 2025, https://pubs.rsc.org/en/content/articlehtml/2015/fo/c5fo00308c
113. Determination of the isoflavone composition and estrogenic activity of commercial dietary supplements based on soy or red clover - PubMed, accessed October 24, 2025, https://pubmed.ncbi.nlm.nih.gov/26023053/
114. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements - PubMed, accessed October 24, 2025, https://pubmed.ncbi.nlm.nih.gov/11285356/